Search results
Results from the WOW.Com Content Network
Illustration of a Hand affected by Rheumatoid arthritis. Rheumatoid Arthritis (RA) is an inflammatory disease that's caused by an autoimmune condition. The condition occurs when bodily cells begin to attack and target their own healthy joint tissues resulting in redness, inflammation, and pain.
Mavrilimumab is a human monoclonal antibody [1] that inhibits human granulocyte macrophage colony-stimulating factor receptor (GM-CSF-R). [2]Mavrilimumab was discovered as CAM-3001 by Cambridge Antibody Technology and is being developed by MedImmune, Inc. [1] as an investigational drug for the treatment of rheumatoid arthritis
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.
Many drugs have more than one name and, therefore, the same drug may be listed more than once. Brand names and generic names are differentiated by capitalizing brand names. See also the list of the top 100 bestselling branded drugs, ranked by sales. Abbreviations are used in the list as follows: INN = International Nonproprietary Name
Although the use of the term DMARDs was first propagated in rheumatoid arthritis (hence their name), the term has come to pertain to many other diseases, such as Crohn's disease, lupus erythematosus, Sjögren syndrome, immune thrombocytopenic purpura, myasthenia gravis, sarcoidosis, and various others.
Despite widespread expectations that the FDA would approve baricitinib for rheumatoid arthritis, [24] in April 2017, the FDA issued a rejection, citing concerns about dosing and safety. [25] [26] In May 2018, baricitinib was approved in the United States for the treatment of rheumatoid arthritis. [9] [12] [10] In March 2020, the US FDA granted ...
Auranofin is used to treat rheumatoid arthritis.It improves arthritis symptoms including painful or tender and swollen joints and morning stiffness. [5] Auranofin is a safer treatment compared to the more common injectable gold thiolates (gold sodium thiomalate and gold thioglucose), but meta-analysis of 66 clinical trials concluded that it is somewhat less effective.